2016 American Transplant Congress Archives

DAAs Rapidly Clear HCV Viremia in Recipients of HCV+ Donor Kidneys.

D. Sawinski, R. Bloom, N. Patel.
De Novo Anti-HLA DSA Characteristics and Subclinical Antibody Mediated Kidney Allograft Injuries.

T. Yamamoto, Y. Watarai, A. Takeda, M. Okada, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, K. Morozumi, K. Uchida, T. Kobayashi.
De Novo DQA/DQB Donor Specific Antibodies (DSA) Is Associated with Allograft Dysfunction in Pediatric Liver Transplantation (LT).

U. Ekong, L. Bow, R. Morotti, J. Gannon, P. Valentino, P. Yoo, M. Rodriguez-Davalos, S. Emre.
De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits of the IgG1κ Subtype in a Kidney Allograft: Protocol Biopsy Findings.

T. Tsuji,¹ M. Miura,² M. Yanai,¹ H. Itami,¹ Y. Ishii,¹ M. Akimoto,¹ Y. Fukasawa.¹
Deceased Donor ABO-Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity.

M. Manook,¹ L. Bradbury,² D. Osei-Bordom,¹ B. Sandhu,¹ T. Maggs,¹ O. Shaw,¹ N. Kessaris,¹ S. Shah,³ A. Dorling, N. Mamode.¹
Deceased Donor Kidney Transplantation in the Setting of Positive Donor-Specific Antibodies.

B. Orandi,¹ J. Montgomery,² E. Kraus,¹ D. Segev,¹ R. Montgomery,¹ N. Alachkar.¹
Deceased Donor Urine C5a Predicts Donor and Recipient Acute Kidney Injury.

B. Schroppel,¹ P. Heeger,² I. Hall,³ M. Doshi,⁴ F. Weng,⁵ P. Reese,⁶ C. Parikh.³
Deceased Non-A₂ Donor ABO-Incompatible Liver Transplantation – Promising Results with Anti-A/B Antibody Reduction Both Pre- and Post-Transplant.

U. Dahlgren,¹ G. Herlenius,¹ J. Mölne,² L. Rydberg,³ O. Samuelsson,⁴ W. Bennet.¹
Deceased Organ Donor Factors Influencing Pancreatic Graft Transplantation and Survival.

M. Sally, M. Ellis, T. Groat, X. Gao, S. De la Cruz, M. Patel, D. Malinoski.
Deceased Organ Donor Management: Does Hospital Volume Matter?

M. Patel,¹ J. Mohebali,¹ M. Sally,² T. Groat,² P. Vagefi,¹ D. Chang,¹ D. Malinoski.²
Deceased Organ Donors with Zero Organs Transplanted: Why and How Can We Improve?

P. Lange,¹ S. Rudich,¹ N. Obaseki,¹ J. Punch.²
Decellularized Rat Liver Scaffolds Support Multilineage Xenogenic and Heterogenic Cell Growth.

W. Hassanein, U. Dhru, J. Woodall, M. Uluer, A. Cimeno, D. Parsell, C. Rivera, S. Klepfer, C. Drachenberg, R. Barth, J. LaMattina.
Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.

S. Pischke,³ V. Proske,¹ S. Polywka,⁴ M. Lütgehetmann,⁴ M. Lang,¹ S. Stauga,¹ L. Fischer,¹ A. Lohse,³ B. Nashan,² M. Sterneck.¹
Defective Post-Reperfusion Metabolic Recovery Directly Associates with Incident Delayed Graft Function.

L. Wijermars, A. Schaapherder, J. Lindeman.
Defining Frailty in Liver Transplant Recipients.

L. Louwers,¹ K. Eid,¹ J. Plescia,¹ N. Presser,¹ J. Muntean,¹ M. Kattan,² K. Chagrin,² C. Miller,¹ D. Kelly.¹
Defining Ischemic Time in Lung Donation After Circulatory Determination of Cardiac Death.

D. Pratt,¹ Z. Kon,² A. Iacono,² J. Kim,² R. Reed,² I. Timofte,² J. Gammie,² S. Pham,² B. Griffith,² P. Sanchez.²
Delayed Graft Function (DGF) Does Not Accelerate Progression of Fibrosis During the First Year After Deceased Donor Kidney Transplantation.

R. Heilman, I. Qaqish, M. Smith, H. Khamash, B. Kaplan, K. Reddy.
Delayed Graft Function (DGF) Doesn't Affect Adversely the Long-Term Survival of Renal Transplantations (RT) from Uncontrolled Donation After Cardiac Death (UDCD) as Compared with RT from Standard Criteria Donor (SCD).

M. Molina,¹ J. Cabrera,² E. Gonzalez,¹ E. Gutierrez,¹ E. Morales,¹ E. Hernandez,¹ M. Praga,¹ A. Andres.¹
Delayed Graft Function Is an Independent Risk Factor for Renal Allograft Rejection.

T. Dienemann, S. Weber, J. Jacobi, K.-U. Eckardt, A. Weidemann.
Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac Allograft Tolerance to be Applied to Recipients of Cadaveric Organs.

M. Tonsho,¹ G. Benichou,¹ R. Yu,¹ S. Boskovic,¹ R. Colvin,^1,2 E. Farkash,² R.-N. Smith,² J. Allan,^1,4 A. Cosimi,¹ T. Kawai,^1,3 J. Madsen.^1,4
Delaying the Induction of Mixed Chimerism Until Two Months After NHP Heart and Kidney Cotransplantation Results in Long Term Survival.

K. Huh,¹ M. Tonsho,¹ P. Spencer,¹ J. Paster,¹ X. Wu,¹ I. Hanekamp,¹ T. Kawai,^1,3 R. Smith,² A. Cosimi,¹ A. Dehnadi,¹ G. Benichou,¹ R. Colvin,^1,2 J. Madsen.^1,4
Delays in the Live Kidney Donor Evaluation Process.

J. Leanza, K. Kumar, J. Tonascia, E. King, A. Massie, D. Segev.
Dendritic Cells and Damage-Associated Molecular Patterns in Aging.

M. Seyda, H. Li, G. Liu, M. Quante, H. Uehara, J. Schuitenmaker, A. Elkhal, S. Tullius.
Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial.

M. Bonani,¹ D. Frey,² J. Brockmann,³ T. Fehr,¹ T. Müller,¹ N. Graf,⁴ R. Wüthrich.¹
DEPTOR Inhibits mTORC1 in CD4⁺ T Cells and Increases Treg Function by Stabilizing Foxp3 Expression.

J. Wedel,^1,2 S. Bruneau,^1,2 D. Briscoe.^1,2
Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014.

S. Mawhorter, N. Shrestha.
Designing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Longterm Heart Allograft Acceptance While Inducing Immune Cell Exhaustion, Treg Induction and Memory Cell Suppression.

E. Sula Karreci,¹ A. Mihali,¹ M. Uehara,¹ A. Kurdi,¹ L. Riella,¹ R. Abdi,¹ H. Fan,² P. Singh,² C. Nathan,² G. Lin,² J. Azzi.¹
Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.

A. Mihali,¹ E. Sula Karreci,¹ A. Kurdi,³ L. Riella,¹ Y. Kawano,³ H. Fan,² P. Singh,² I. Ghobrial,³ C. Nathan,² G. Lin,² J. Azzi.¹
Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10.

J. Ho,¹ A. Sharma,² R. Mandal,³ D. Wishart,³ C. Wiebe,¹ L. Storsley,¹ M. Karpinski,¹ I. Gibson,⁴ P. Nickerson,¹ D. Rush.¹
Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation.

J.-W. Seo, S.-Y. Kim, Y.-G. Kim, Y.-H. Jeong, Y.-H. Lee, J.-Y. Moon, T.-W. Lee, C.-G. Ihm, S.-H. Lee.
Detection of Venous Thrombi by Microdialysis Catheters and Angiographic Guided Thrombus Extraction in Two Solitary Pancreas Transplants.

G. Kjosen,¹ R. Horneland,² E. Aandahl,² O. Oyen,² T. Tonnessen,^1,3 H. Hakon.¹
Determinants of 1 Year Graft Loss After Pre Kidney Transplant Bariatric Surgery.

G. Mour, J. Zhang, Z. Su, D. Taber, P. Mauldin, T. Srinivas.
Developing a PCR-Based System to Access the Correlation of Local Chimerism and Fate of the Vascularized Composite Allotransplant.

X.-T. Huang,¹ H.-Y. Cheng,¹ C.-F. Lin,¹ S.-S. Qiu,² L.-Y. Shih,¹ F.-C. Wei.^1,2,3
Development and Validation of a Molecular Microscope Diagnostic System (MMDx) for Heart Transplant Biopsies.

P. Halloran,¹ D. Kim,¹ A. Loupy,² J.-P. Duong Van-Huyen,² P. Bruneval,³ L. Potena,⁴ O. Leone,⁴ J. Reeve.¹
Development of a Sequencing-Based Cytomegalovirus UL55 Glycoprotein B (gB) Genotyping Assay.

S. Cowden, K. Grantham, I. Caton, J. Hester, M. Altrich, S. Kleiboeker.
Development of a Vascularized Thymus-Sternum Composite Tissue Allograft Model in Non-Human Primates.

N. O'Neill, S. Sendil, Y. Zhao, A. Hershfield, I. Tatarov, G. Braileanu, W. Hassanein, D. Parsell, A. Azimzadeh, L. Burdorf, R. Pierson, A. Nam.
Development of an Integrated Transplant Data Mart for Customized Data Reporting.

R. Patzer, K. Little, J. Kirsch, J. Weaver, A. Adams.
Development of Diabetic Glomerulosclerosis (DMGS) After Kidney Transplantation (KTX).

F. Cosio, L. Cornell, M. Stegall.
Diabetes Mellitus and Kidney Transplant Outcomes.

A. Mehrnia,¹ A. Wang,¹ W. Chaiwatcharayut,² E. Huang,¹ S. Bunnapradist.¹
Diabetes Mellitus Predicts Outcome in Obesity After Kidney Transplantation.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
Diabetes Mellitus Status of the Donor and Prolonged Cold Ischemia Time Have a Synergistic Negative Effect on Graft Survival After Liver Transplantation.

I. Brüggenwirth,^1,2 N. Dolgin,¹ P. Martins,¹ B. Movahedi,¹ A. Ahearn,¹ R. Porte,² A. Bozorgzadeh.¹
Diagnosis of Pulmonary Nocardiosis: A Single Center Study.

D. Wray,¹ S. Win,² M. Heincelman,¹ L. Steed,¹ J. Cantey.¹
Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada.

O. Bignall II,^1,2 A. Pai,² S. Amaral,³ S. Furth,³ N. Bergman,² J. Goebel,⁴ The TAKE-IT Study Investigators, B. Foster.⁵
Differences in Tacrolimus Troughs and Doses Between Caucasians and African Americans with Two CYP3A5 Loss-of-Function Alleles: Looking Beyond CYP3A5 Expression.

W. Oetting,¹ D. Schladt,² W. Guan,¹ R. Remmel,¹ C. Dorr,² K. Sanghavi,¹ A. Matas,¹ R. Mannon,³ A. Israni,² P. Jacobson,¹ For DeKAF Genomics,¹ GEN-03 Investigators.¹
Differences in the Prevalence of Food Allergies After Liver and or Bowel Transplantation.

K. Khan, C. Desai, S. Kaufman, A. Kroemer, J. Hawksworth, R. Girlanda, T. Fishbein, C. Matsumoto.
Differential Characteristics of Kidney Transplant Recipients According to 1-Year Chronic Kidney Disease Stage 3a and Stage 3b Graft Function.

C. Baek,¹ H. Kim,¹ W. Yang,¹ D. Han,² S.-K. Park.¹
Differential Effect of Delayed Graft Function (DGF) on Kidney Transplant Outcomes: When Does DGF Not Make a Difference?

M. Khan,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context.

N. Mooney,^1,2 A. Cross,^1,2 J. Lion,^1,2 A. Haziot,^1,2 D. Glotz.^1,2,3
Difficult to Place Livers: Implications for Expanding the Donor Pool.

E. Edwards,¹ A. Harper,¹ J. Rosendale,¹ J. Eason.
Diffuse Extent of Peritubular Capillaritis in Late Antibody Mediated Rejection Is Associated with More Severe Chronic Allograft Damage.

Z. Kikić,¹ F. Eskandary,¹ H. Herkner,² R. Oberbauer,¹ G. Bond,¹ H. Regele,³ G. Böhmig,¹ N. Kozakowski.³
Digital Kidney Biopsy Evaluation: Quantification of Macrophage Prevalence in a Cross Sectional Study.

J. Schmitz,¹ A. Khalifa,¹ H. Haller,² H. Kreipe,¹ F. Feuerhake,¹ J. Bräsen.¹
Dilution of Patient Sera Improves MFI Correlation with Complement Fixation in Solid Phase Assay Assessment.

C. Castleberry,¹ D. Phelan,² K. Simpson,¹ T. Mohanakumar,³ C. Canter.¹
Direct Alloimmunity Is Driven by Recipient APCs Displaying Donor MHC Molecules.

J. Marino,¹ J. Paster,¹ P. Crosby,¹ M. Uehara,² S. Mordecai,¹ R. Abdi,² G. Tocco,¹ G. Benichou.¹
Direct Detection of T and B Memory Lymphocytes Reveals HCMV Exposure That Serum Antibodies Fail to Identify.

S. Sundararaman, F. Terlutter, T. Nowacki, R. Caspell, P. Lehmann.
Direct IL-33 Stimulation of T Regulatory Cells via Suppression of Tumorigenicity 2 (ST2) Is Required for Effective Control of Alloimmune Responses.

X. Zhang,^1,3 B. Matta,¹ D. Reichenbach,² B. Blazar,² H. Turnquist.¹
Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.

N. Goyal, W. Huepfel, A. Tierney, N. Issa, J. Lake, J. Thompson, M. Hassan, H. Ibrahim, A. Kukla.
Distinct Effects of Chronic Hyperglycemia on Cellular and Humoral Alloresponses In Vivo.

N. Bishop,¹ K. Beard,² R. Gill.²
Distinct Phenotype and Function of Plasmacytoid Dendritic Cells from Kidney Allografts in Tolerant Recipients.

N. Oh,^1,2 C. Yang,^1,2,3 M. Tonsho,^1,2 D. Ndishabandi,^1,2,3 P. Russell,^1,2 R. Colvin,^1,3 J. Madsen,^1,2 A. Alessandrini.^1,2
Distinctive Roles of Gsk3 Inhibitory Phosphorylation in Liver Inflammatory Immune Response and Hepatocellular Injury Against Ischemia Reperfusion.

H. Zhou,^1,2 J. Zhu,¹ S. Yue,¹ R. Busuttil,¹ J. Kupiec-weglinski,¹ L. Lu,² Y. Zhai.¹
Diversity of Influenza Antibody Repertoire in Transplant Recipients with Natural Influenza Infection.

V. Ferreira, A. Chruscinski, S. Han, A. Humar, D. Kumar.
DNA Methylation Patterns and Association with Graft Injury Severity Post Liver Transplantation.

R. Gehrau, S. Bontha, V. Mas, D. Maluf.
Do All cPRA 100% Candidates Have Equal Access to Organ Allocation?

H. Gebel,^1,2 S. Gustafson,¹ D. Segev,^1,3 B. Kasiske,¹ A. Israni.¹
Do Highly Sensitized Recipients Benefit from the Immunological Advantages of Zero Mismatched (0MM) Deceased Donors (DD) Kidney Allografts?

N. Elfadawy,¹ S. Flechner,² J. Schold.²
Do Morbidly Obese Patients Have an Increased Risk of Infection Post-Kidney Transplant?

S. Strout, N. Pilch, T. Veasey, R. Miller, J. Fleming, H. Meadows, C. Mardis, B. Mardis, P. Baliga, A. Posadas, J. McGillicuddy, D. Taber.
Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?

M. John, I. Dortonne, B. Kim, C. Li, M. Killackey, A. Paramesh, B. Lee, R. Zhang, G. Parker, J. Buell.
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.

S. Bhutani,¹ A. Ponnusamy,² Q. Tak,¹ S. Shah,¹ J. Worthington,¹ A. Summers,¹ K. Poulton,¹ D. Van Dellen,¹ M. Morton,¹ M. Picton.¹
Do We Need Radioisotope Renography in Evaluation of Split Renal Function in Living Kidney Donors?

Y. Yoon,¹ H. Lee,¹ D. Joo,² K. Huh,² M. Kim,² S. Kim,² Y. Kim,² W. Han.¹
Does DCD Donor Time-to-Death After Withdrawal of Support Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States.

J. Scalea, L. Fernandez, A. D'Alessandro, M. Anderson, D. Foley, J. Mezrich.
Does Donor and Recipient Age Disparity Make a Difference with Expanded Criteria Donors?

M. Khan,¹ K. Jones,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Does Drain Placement Reduce the Risk of Peri-Graft Collections and Wound Complications After Kidney Transplant?

S. Cimen,¹ S. Cimen,¹ K. Tennankore,² A. Imamoglu,³ I. Alwayn.¹
Does Location Matter for Withdrawal of Donation After Cardiac Death Donors ?

K. Mekeel,¹ W. Garrison,² J. Trageser,² J. Berumen,¹ L. Stocks,² A. Hemming.¹
Does Post-Transplant Adherence Come at a Cost?

K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
Does Pre-Emptive Transplantation Improve Survival Compared to Transplantation After Dialysis Among Deceased Donor Kidney Recipients?

J. Tao, C. Wu, W. Bannister, M. Schnitzler, A. Bonagura, B. Laihinen, F. Irwin.
Does Pre-Operative Transarterial Chemoembolization(TACE) Increase the Risk of Early Post-Operative Pancreatitis After Liver Transplantation(LT)?

V. Kirchner, L. Zhang, T. Dunn, E. Finger, M. Hassan, R. Kandaswamy, J. Lake, P. Liu, E. Minja, O. Serrano, A. Pugalenthi, J. Thompson, K. Yadav, W. Payne, T. Pruett, S. Chinnakotla.
Does Rising MELD Score Convey Worse Liver Transplant Outcome?

A. Rahnemai-Azar, J. Perkins, M. Montenovo, T. Pearson, R. Bakthavatsalam, S. Rayhill, A. Dick, J. Reyes, L. Sibulesky.
Does Social Support Predict Clinical Outcomes Post-Transplantation? A Systematic Review and Meta-Analysis.

K. Ladin,¹ A. Daniels,¹ M. Osani,² R. Bannuru.²
Don't Judge a Book by Its Cover: Normal Liver Enzymes After Transplantation Can Be Associated with Pathologies Requiring Intervention.

C. Sanchez,¹ S. Kumer,² S. Olson,¹ R. Gilroy,¹ T. Schmitt,² B. Kane,² R. Taylor.¹
Donation After Cardiac Death Dose Not Impact Short and Long Term Graft Outcomes in Simultaneous Pancreas and Kidney Transplantation.

T. Alhamad,¹ A. Taha,² K. Lentine,² J. Wellen,¹ J. Garonzik-Wang,¹ D. Brennan.¹
Donor AKI Does Not Adversely Affect the Outcome Following DCD Kidney Transplant.

I. Qaqish, D. Haakinson, K. Reddy, M. Smith, H. Khamash, R. Heilman.
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.

A. Babu, A. Androeu, S. Daga, R. Higgins, D. Mitchell, D. Briggs, N. Khovanova, N. Krishnan.
Donor Interstitial Fibrosis and Tubular Atrophy (IFTA) Are Not Independent Risk Factors for a Lower GFR at One Year.

R. Heilman, I. Qaqish, M. Smith, H. Khamash, B. Kaplan, K. Reddy.
Donor Risk Index for Intestinal & Multi-Visceral Transplantation.

G. Zeng,¹ M. Chen,² X. Zhao,³ D. Landsittel,² H. Sogawa.⁴
Donor Sharpin Expression Modulates TNFα Mediated Inflammation and Cardiac Allograft Rejection in Mice.

R. Ang,¹ P. Heeger,² A. Ting.¹
Donor Smoking Increases Kidney Allograft Recipient Mortality in a National Population Cohort Analysis.

H. Gillott,¹ F. Jackson-Spence,¹ S. Tahir,¹ F. Evison,² J. Nath,³ A. Sharif.³
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.

L. Requião-Moura,¹ M. Afonso,² A. Sakashita,³ M. Silva,¹ A. Matos,¹ A. Pacheco-Silva.¹
Donor Specific Antibody Used to Predict Crossmatch Results: A Clinically Useful Algorithm Derived from the College of American Pathologists Survey.

S. Wrenn,¹ D.-S. Hain,² S. Harm,² S. Hillyard,² D. Shah,² P. Hammond,² C. Marroquin,¹ M. Fung.²
Donor Transmited Rabies Outbreak Involving Four Transplant Recepients in Kuwait and Saudi Arabia.

H. Elsiesy,^1,2 I. Hussain,³ F. Abaalkhail,^1,2 W. Al-Hamoudi,¹ H. Elbeshbeshy,¹ M. Al Sebayel,¹ D. Broering,¹ A. Elgohary,¹ S. Al Fawaz,⁴ S. Althawadi,⁵ J. Alotaibi,⁴ H. AlHindi,⁵ P. Nair,⁶ T. Al- Otaibi,⁶ N. Nampoory,⁶ L. Orciar,⁷ A. Velasco-Villa,⁷ P. Yager,⁷ T. Smith,⁷ W. Carson,⁷ M. Niezgoda,⁷ A. Wadhwa,⁷ R. Edgar Condori,⁷ Y. Li,⁷ R. Franka,⁷ M. Halim,⁴ R. Willoughby.⁸
Donor-Candidate Mismatch in Age, Sex, HLA, and Body Size Inform a Calculator for Kidney Graft Survival.

J. Kalbfleisch,¹ V. Ashby,¹ A. Leichtman,² M. Rees,³ P. X.-L. Song,¹ A. Sakhuja,¹ M. Bray,¹ R. Eikstadt,¹ A. Goulding,¹ W. Wang.¹
Donor-Derived Monocytes Migrate to the Contralateral Lung and Cause Neutrophilia Following Single Lung Transplant.

S. Chiu, Z. Zheng, H. Sun, M. DeCamp, Jr, G. Budinger, H. Perlman, A. Misharin, A. Bharat.
Donor-Derived Toll-Like Receptor-Dependent Intravascular Monocytes Cause Primary Lung Graft Dysfunction.

S. Chiu, Z. Zheng, H. Sun, M. DeCamp, Jr, G. Budinger, H. Perlman, A. Misharin, A. Bharat.
Donor-Derived Toxoplasmosis in Solid Organ Transplant 2008 – 2015: Opportunities for Improvement.

C. Wolfe,¹ A. Wilk,² S. Tlusty,² C. Sifri,¹ M. Morris,¹ A. Mehta,¹ D. Kaul.¹
Donor-Recipient Absolute Weight Mismatch and the Risk of Graft Loss in Renal Transplantation.

A. Miller,¹ B. Kiberd,¹ I. Alwayn,² K. Tennankore.¹
Donor-Recipient Race Matching Is Not Associated with Recipient Survival Following Heart Transplantation.

C. Evans,¹ P. Sanchez,¹ Z. Kon,¹ E. Feller,² B. Griffith,¹ S. Pham.¹
Donor-Specific Antibodies in a Single-Center Pediatric Kidney Transplant Population – Incidence and Risk Factors.

M. Bock,¹ L. Starkey,¹ C. Buchanan,² E. Steinberg,² A. Sikora,² K. McKinnon,² M. Wachs,² J. Goebel.¹
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).

M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.

Y. Chang,^1,3 C. Chinchilla-Reyes,² M. Koss,^1,2 M. Nowicki.^1,2
Down-Regulated of Circulating miR-29b, miR-185 and NR_073415.2 in Post-Transplanted Patients with Cytomegalovirus Infection May Serve as Novel Biomarkers for Early Diagnosis.

A. Yang, W. Ju, Z. Guo, C. Wu, J. Lin, M. Chen, R. Deng, E. Chen, Y. Gao, X. Zhu, X. He.
DSA After Transplant Increases Risk of Renal Allograft Failure Independent of Concurrent Biopsy Results: The DEKAF Study Data.

J. Cecka,¹ J. Grande,² F. Cosio,² R. Leduc,³ The DeKAF Study Group.
Dual Kidney Transplants as Policy to Optimize the Allocation of Marginal Donor Kidneys: Analysis of the French Cohort Since 2002.

E. Savoye,¹ R. Snanoudj,² C. Hiesse,³ M.-N. Peraldi,⁴ A. Durrbach,⁵ N. Ouali,⁶ M. Durand,⁷ L. Badet,⁸ M.-A. Macher.¹
Duodenal Graft Complications After Pancreas Transplant: Evolving Management.

D. Al-Adra,¹ J. Laurence,² A. Norgate,¹ N. Goldaracena,¹ M. Marquez,¹ A. Barbas,¹ M. Dib,¹ M. Selzner,¹ M. Cattral.¹
Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation (LDLT) in Children.

E. Przybyszewski,¹ S. Lobritto,¹ M. Martinez,¹ J. Vittorio,¹ A. Fox,¹ B. Samstein,² T. Kato,¹ A. Griesemer,¹ J. Emond.¹
Dynamic Detection of Anti-HLA Antibodies Can Predict aGVHD and OS in HLA-12/12 Matched Unrelated-Donor Allo-HSCT for Hematological Malignancies.

J. He,¹ Z. Pan,¹ X. Yuan,¹ Y. Li,¹ X. Wu,² W. Zhu,² X. Bao,¹ Q. Zhao.²
Dynamics of Delayed Graft Function-Associated Risk in Deceased Donor Kidney Transplantation.

C. Liao, A. Massie, S. Bae, A. Muzaale, D. Segev.
Dysfunctional Production of Adipocytokines in Obesity Results in Inferior Oncologic Outcomes from Hepatocellular Carcinoma Following Liver Transplantation.

A. Mathur, E. Presbyskowski, D. Carpenter, E. Zorn, J. Guarrera, B. Samstein, A. Griesemer, K. Halazun, Y. Veras, K. Tomoaki, J. Emond.